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Abstract
Non-therapeutic medical interventions on the bodies of children born with disorders of
sex development (DSD)/intersex variations have been subject to increasing critical
scrutiny. In response to recent criticism directed at the United Kingdom, and early
moves to consider reform, we report on a freedom of information exercise that sought
to evaluate whether National Health Service England is meeting international standards
on optimal clinical management of DSD/intersex variations. The study explored what
medical protocols are being followed to help inform potential reform, particularly with
regard to non-therapeutic surgery. While the exercise revealed limited examples of
promising practice, current protocols in the majority of Trusts appear unlikely to meet
the complex needs of these children. We identify areas where significant improvement is
needed, including data management, consistency in guideline use, composition of mul-
tidisciplinary teams and addressing disciplinary hierarchies within teams. These concerns
sharpen criticisms of the lack of recognition of children’s rights in this context.
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Introduction1
International law and civil society have become increasingly critical of non-therapeutic
medical interventions on the bodies of children born with intersex variations. This has
been provoked by evidence of the harms occasioned by such surgery and increasing
awareness of the children’s rights.2 In the last decade, condemnation has come from the
Council of Europe Commissioner for Human Rights; United Nations (UN) Special
Rapporteur on Torture and Other Cruel, Inhuman or Degrading Treatment or Punish-
ment; UN Committee on the Rights of the Child; and the UN Committee on the Rights of
1. Nomenclature disclaimer: Terminology in this field is highly contested. While medical
professionals refer to disorders or differences of sex development (DSD), activists and
human rights campaigners reject this terminology for its unnecessary pathologising effect.
Instead, those critical of ‘DSD’ use a variety of terms including intersex, intersex variations
and variations of sex characteristics. This article uses intersex variations as its preferred
terminology. However, as it collected data from medical professionals, it uses ‘DSD’ to
engage with that data when appropriate. For discussion of this issue, see T. Lundberg, P.
Hegarty and K. Roen, ‘Making Sense of “Intersex” and “DSD”: How Laypeople Understand
and Use Terminology’, Psychology & Sexuality 9(2) (2018), pp. 161–173; S. Munro et al.,
Intersex, Variations of Sex Characteristics, and DSD: The Need for Change (Huddersfield:
University of Huddersfield, 2017). We also note that a 10-year update to the Chicago
Consensus Statement failed to reach clear agreement about why there is controversy
surrounding the term DSD. N. Delimata, M. Simmonds, M. O’Brien, et al., ‘Evaluating the
Term “Disorders of Sex Development”: A Multidisciplinary Debate’, Social Medicine 11(3)
(2017), p. 98.
2. See, for example, M. Carpenter, ‘The “Normalization” of Intersex Bodies and “Othering” of
Intersex Identities in Australia’, The Journal of Bioethical Inquiry 15 (2018), p. 487; M.
Carpenter, ‘Intersex Variations, Human Rights, and the International Classification of
Diseases’, Health and Human Rights 20(2) (2018), p. 1; E. Horowicz, ‘Intersex Children:
Who Are We Really Treating?’, Medical Law International 17(3) (2017), p. 183; K. Karzakis,
Fixing Sex: Intersex, Medical Authority, and Lived Experience (Durham, NC and London:
Duke University Press, 2009); E. Feder, Making Sense of Intersex: Changing Ethical
Perspectives in Biomedicine (Bloomington, IN: Indiana University Press, 2014); A. Fausto-
Sterling, Sexing the Body: Gender Politics and the Construction of Sexuality (New York, NY:
Basic Books, 2000); M. Fox and M. Thomson, ‘Bodily Integrity, Embodiment, and the
Regulation of Parental Choice’, Journal of Law and Society 44(4) (2017), pp. 501–531; F.
Garland and M. Travis, ‘Legislating Intersex Equality: Building the Resilience of Intersex
People Through Law’, Legal Studies 38(4) (2018), pp. 587–606; K. Roen, ‘Intersex or Diverse
Sex Development: Critical Review of Psychosocial Health Care Research and Indications for
Practice’, Journal of Sex Research 56 (2019), pp. 511–528.
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Persons with Disabilities.3 In light of such criticism, and the work of activist and patient
organisations, Malta, Portugal and now Germany have prohibited such interventions
until the intersex individual is able to provide informed consent and a growing number
of other states are considering similar reforms.4 The focus on informed consent accords
with the growing awareness of children’s rights, particularly their rights to bodily integ-
rity and to meaningfully participate in decisions that affect them.5
Within the national context, in 2016 the UK Government responded to criticism from
the UN Committee on the Rights of the Child by characterising intersex issues as solely
the responsibility of the National Health Service (NHS).6 It is arguable that this fails to
acknowledge Convention obligations as a signatory state and signalled an unwillingness
to take responsibility for these issues.7 Subsequently, however, the Government
launched a call for evidence to investigate the needs of intersex people, specifically
addressing their experiences with the medical profession.8 Within the NHS, the clinical
reference group governing this area falls under the umbrella of ‘specialised endocrinol-
ogy’. This team is yet to commission any policies despite there being international
consensus on the diagnosis and care of persons with intersex variations.9 A consistent
3. For an overview of these legal documents, see F. Garland, N. Samuelsen and M. Travis, Law
and Intersex in Norway: Challenges and Opportunities (2019). Available at: https://pdfs.
semanticscholar.org/e3d0/1b8a91c05d9c29f628cc8ccc13b820f4fbf9.pdf (accessed 14
November 2020); M. Sudai, ‘Changing Ethical and Legal Norms in the Management of
Differences of Sex Development’, The Lancet Diabetes and Endocrinology 5(10) (2017),
pp. 764–766.
4. See Malta’s Gender Identity, Gender Expression and Sex Characteristics Act (2015);
Portugal’s Law No. 75/XIII/2 2018; and Germany’s Law on the Protection of Children
with Variants of Gender Development (2021). Both California and Iceland have had bills
recently introduced which are designed to prohibit such interventions but which have been
unsuccessful.
5. Fox and Thomson, ‘Bodily Integrity, Embodiment’; A. Daly, Children, Autonomy and the
Courts: Beyond the Right To Be Heard (Leiden: Brill, 2018).
6. Stop IGM. Geneva > UK Questioned Over Intersex Genital Mutilations by UN Committee
on the Rights of the Child – Gov Non-Answer þ Denial. Available at: http://stop.
genitalmutilation.org/pages/Geneva-UK-Questioned-over-Intersex-Genital-Mutilations-by-
UN-Committee-on-the-Rights-of-the-Child-Gov-Non-Answer-Denial2016 (accessed 16
July 2019); F.T. Goldhill, ‘72nd Session of the UN Committee on the Rights of the Child
23 May 2016’. Available at: http://stop.genitalmutilation.org/post/UK-Questioned-over-
Intersex-Genital-Mutilations-by-UN-Committee-on-the-Rights-of-the-Child (accessed 4
September 2019)
7. F. Garland and M. Travis, ‘Making the State Responsible: Intersex Embodiment, Medical
Jurisdiction, and State Responsibility’, Journal of Law and Society 47(2) (2020), pp. 298–324.
8. Government Equalities Office, Variations in Sex Characteristics Call for Evidence (2019).
Available at: https://www.gov.uk/government/consultations/variations-in-sex-
characteristics-call-for-evidence (accessed 1 December 2020).
9. P.A. Lee, C.P. Houk, S.F. Ahmed, et al., ‘In Collaboration with the Participants in the
International Consensus Conference on Intersex Organized by the Lawson Wilkins
Pediatric Endocrine Society and the European Society for Paediatric Endocrinology,
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and coherent healthcare approach to intersex variations in the United Kingdom (UK)
may, therefore, be lacking. In response, the NHS has developed a specialised commis-
sioning group looking specifically at intersex variations.
This article is provoked by these national and international contexts, and we address
current practice in England. NHS England is only one of the four health systems in the
United Kingdom. Since 1999, health policy is part of devolved powers and similar
exercises are warranted in the other health systems. Currently, there is little to no data
on how NHS England manages children with intersex variations. Consequently, it has
been difficult to effectively evaluate how far NHS England is meeting current interna-
tional standards on clinical management, if at all. To address this, we undertook a
freedom of information (FoI) exercise which sought to explore what medical protocols,
if any, NHS England hospitals are following. Before addressing our methodology and
results, the following two sections situate intersex variations within the socio-medico
context and consider international guidelines for best practice in this area.
Intersex variations
Intersex is an umbrella term referring to a diverse range of congenital bodily variations
that at the chromosomal, gonadal, hormonal and/or anatomical level do not neatly fit into
the binary categories of male or female. These variations may become apparent at
different life stages – and some may never come to know about their variation10 –
although they most commonly present at birth or during adolescence. While adolescents
are often referred by their general practitioners (GPs) to specialists where puberty is
delayed, absent, or where unexpected changes occur, infants are typically born in sec-
ondary care and identified immediately after birth or at some point within the newborn
period as a result of atypical genitalia.11 The three most common causes of newborn
genital variations are hypospadias, where the urethral opening occurs in a place other
than at the tip of the penis or above the vaginal opening; XX congenital adrenal hyper-
plasia (CAH); and partial androgen insensitivity syndrome (PAIS). CAH affects the
adrenal gland’s production of hormones. A side effect of this adrenal problem can be
the overproduction of testosterone which has a virilising effect on foetuses with XX
chromosomes and ovaries. Infants are born with a larger than average clitoris or atypical
genitalia. AIS affects individuals with XY chromosomes who are unable to process the
androgens (hormones) released by their gonads. While complete AIS results in external
female genitalia but no female internal reproductive organs (symptoms often not appear-
ing until puberty), in PAIS there may be some degree of masculinisation resulting in
atypical genitalia.
Consensus Statement on the Management of Intersex Disorders’, Paediatrics 118(2) (2006),
e488–e500.
10. T. Jones, ‘Intersex Studies: A Systematic Review of International Health Literature’, Sage
Open 8(2) (2018), pp. 1–22.
11. J.H. Davies and T. Cheetham, ‘Recognition and Assessment of Atypical and Ambiguous
Genitalia in the Newborn’, Archives of Diseases in Childhood 102 (2017), pp. 968–974, p. 2.
Some intersex variations may be identified prenatally.
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It is difficult to state the exact proportion of the population with an intersex variation.
This is largely due to the politics and semantics of what variations are and are not
included under the intersex/disorders of sex development (DSD) umbrella as well as
inconsistencies in reporting. The most commonly cited figure is 1.7% of all live births,
an estimate made by Anne Fausto-Sterling and her research team.12 Fausto-Sterling
notes that this is an order of magnitude estimate taken from a wide variety of popula-
tions. This figure has been replicated in many academic and activist texts including the
Council of Europe’s ‘Human Rights and Intersex People: Issue Paper’.13 Some scholars,
like Sax, have criticised this figure for overinclusion, contesting the intersex status of
genetic variations like Klinefelter syndrome (XXY) and Turner syndrome (X), and other
variations including late-onset adrenal hyperplasia and vaginal agenisis.14 Excluding
these variances, Sax estimated a lower figure of 0.018%.15
Since replacing ‘intersex’ with ‘DSD’ in medical contexts, the inclusion of Klinefel-
ter syndrome, Turner syndrome and late-onset adrenal hyperplasia is considered less
controversial. The Chicago Consensus statement, for example, sought to ground the
categorisation of DSD in genetic differences, explicitly including both Klinefelter and
Turner syndromes.16 However, controversy remains among DSD scientists as to whether
genetic variation or genital anatomy should be the primary factor in defining category
membership. Consequently, both Turner and Klinefelter syndromes continue to have a
liminal position in relation to DSD categorisation and these categorisations therefore
remain a contested and political act.17 Regarding genital variations, recent medical
guidelines, including the ‘Global disorders of sex development update since 2006’
statement, have noted that ‘There are no clear estimates of the incidence rate of subjects
presenting with atypical genitalia at birth, and only a proportion of them present a major
challenge regarding male or female assignment’.18 Nonetheless, they rely on Sax to
estimate an incidence rate of around 1 in 4500–5500. Of these, Sax draws on Fausto-
Sterling’s figures to estimate that AIS occurs in 8 in 100,000 live births and CAH with
genital variations also occurs in 8 in 100,000 live births.19
The inclusion of hypospadias within ‘intersex’ is another point of controversy.
Hypospadias and cryptorchidism (one or more undescended testes) are not routinely
12. Fausto-Sterling, ‘Sexing the Body’, p. 51; M. Blackless et al., ‘How Sexually Dimorphic Are
We? A Review Article’, American Journal of Human Biology 12 (2000), pp. 151–166.
13. Council of Europe, Human Rights and Intersex People: Issue Paper. 1st edn (Strasbourg:
Council of Europe, 2015).
14. L. Sax, ‘How Common Is Intersex? A Response to Anne Fausto-Sterling’, The Journal of Sex
Research 39 (2002), pp. 174–178.
15. Op. cit.
16. D.A. Griffiths, ‘Shifting Syndromes: Sex Chromosome Variations and Intersex
Classifications’, Social Studies of Science 48 (2018), pp. 125–148.
17. Op. cit.
18. P. Lee, A. Nordenström, C.P. Houk, et al., ‘Global Disorders of Sex Development Update
Since 2006: Perceptions, Approach and Care’, Hormone Research in Paediatrics 85 (2016),
pp. 158–180 at 159.
19. Op. cit. 16, p. 159; Sax, ‘How Common Is Intersex?’ 13, p. 275.
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understood as DSD unless the individual presents proximal (severe) hypospadias (where
the urethra opening is at the bottom of the shaft or on the scrotum) and it is accompanied
with cryptorchidism. Instead, hypospadias is more likely to be understood as a symptom,
rather than a condition, or syndrome, per se. Accordingly, hypospadias is not always
medicalised, and, importantly, there is current evidence of disagreements among UK
DSD clinicians as to whether and why they should be subject to medical intervention.20
The 2006 international consensus statement notes that if ‘all congenital genital anoma-
lies are considered, including cryptorchidism and hypospadias, the rate may be as high as
1:200 to 1:300’.21 Overall, existing debates about the incidence rates of DSD variations
tend to assume that healthcare providers have integrated efficient reporting systems into
their practice, an assumption we challenge in our discussion.
Regardless of the technicalities of classification, healthcare practitioners construct the
presence of atypical genitalia as a state of emergency requiring immediate interven-
tion.22 In part, this is because the majority of protocols around intersex care and man-
agement were based predominantly on patients with XX CAH, which, as we shall shortly
discuss, do necessitate elements of emergency care.23 In some instances, CAH can result
in salt-wasting where the newborn requires life-saving hormonal treatment. Accordingly,
where a newborn presents with atypical genitalia it is imperative that tests are performed
to rule out or treat salt-wasting CAH. Problematically, however, healthcare practitioners
have routinely presented ‘fixing’ genitalia as an integral part of treating CAH.24 Yet, as
Garland and Travis note, treatment for salt-wasting and normalising genital surgeries are
entirely separate matters and should not be conflated. Salt-wasting requires immediate
hormonal treatment, not surgical intervention, while normalising genital surgeries can
easily be deferred until the individual is able to take part in the decision-making pro-
cess.25 Scholarship has criticised this conflation for enabling the medical profession to
20. K. Roen and P. Hegarty, ‘Shaping Parents, Shaping Penises: How Medical Teams Frame
Parents’ Decisions in Response to Hypospadias’, British Journal of Health Psychology 23(4)
(2018), pp. 967–981.
21. Lee, Nordenström, Houk, et al., ‘Global Disorders of Sex Development Update Since 2006’,
p. 159.
22. F. Garland and M. Travis, ‘Bodies in Time(s): Vulnerability, Temporality and Intersex
Embodiment’, in C. Dietz, M. Travis and M. Thomson, eds., A Jurisprudence of the Body
(London: Palgrave, 2020), p. 119.
23. L. Fleming, K. Knafl, G. Knafl, et al., ‘Parental Management of Adrenal Crisis in Children
with Congenital Adrenal Hyperplasia’, Journal for Specialists in Pediatric Nursing 22(4)
(2017), e12190; Feder, ‘Making Sense of Intersex’. Note XY infants can have CAH but are
not then classed as having a DSD or being intersex and do not typically have atypical genital
anatomy. A revealing discussion of the contrasting care parents provide to boys and girls
with CAH is provided in L. Fleming, K. Knafl, and M. Van Riper, ‘How the Child’s Gender
Matters for Families Having a Child with Congenital Adrenal Hyperplasia’, Journal of
Family Nursing 23(4) (2017), pp. 516–533.
24. Garland and Travis, ‘Bodies in Time(s)’, pp. 124–125.
25. Op. cit., p. 125.
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frame all intersex variations as discrete emergencies to ‘create a sense of immediacy that
does not just justify, but necessitates, medical intervention’.26
Problematically, much of the approach to intersex management has been extrapolated
from experiences of people with CAH.27 Since the 1950s, standard medical practice has
recommended surgical ‘normalising’ procedures typically within the first 12–18 months
of life28 in order to ‘fix’ intersex children and allow them to lead ‘normal’ lives. Yet,
these interventions are non-therapeutic and unnecessary as outside of salt-wasting CAH
almost all intersex variations are benign.29 Hypospadias (including proximal hypospa-
dias) and AIS, for example, do not threaten the life or health of the individual, and
instead treatment is provided to cure social and perceived psychological anxieties; the
need for boys to be able to urinate while standing features as a core concern behind
surgical interventions for hypospadias.30
The need to defer surgeries is supported by evidence that these procedures result in a
range of physical and psychological harms. Early surgical intervention can typically
initiate a series of follow-up and corrective surgeries for the first 18 years of life with
one study finding 89% of genitoplasties (planned as one-stage procedures) required at
least one further major surgery.31 These surgeries can result in scarring, pain, stenosis,
dissatisfaction with genital aesthetics and reduction in sexual functioning.29 Early
removal of testes due to perceived cancer risks can lead to reliance on artificial
hormones leading to conditions such as osteoporosis.32 While guidelines recommend
26. Op. cit., pp. 120–121. See also M. Newbould, ‘When Parents Choose Gender: Intersex,
Children and the Law’, Medical Law Review 24(4) (2017), pp. 474–449; J. Garland and S.
Slokenberga, ‘“Minorities Within Their Own Families” Protection of the Rights of Children
with “Intersex Conditions”’, Europe Medical Law Review 27(3) (2018), pp. 482–508;
Amnesty International, ‘First, Do No Harm: Ensuring the Rights of Children with
Variations of Sex Characteristics in Denmark and Germany Report’ (2017). Available at:
https://www.amnesty.org/download/Documents/EUR0160862017ENGLISH.PDF (accessed
8 July 2020).
27. Feder, ‘Making Sense of Intersex’.
28. Lee, Nordenström, Houk, et al., ‘Global Disorders of Sex Development Update Since 2006’.
29. K. Zillén, J. Garland and S. Slokenberger, The Rights of Children in Biomedicine:
Challenges Posed by Scientific Advances and Uncertainties, Committee on Bioethics
of the Council of Europe Report (2017). Available at: http://www.diva-portal.org/
smash/get/diva2:1065442/FULLTEXT01.pdf (accessed 1 December 2020). F. Haynes,
‘Introduction’, in F. Haynes and T. McKenna, eds., Unseen Genders: Beyond the
Binaries (New York, NY: Peter Lang, 2001).
30. Karzakis, ‘Fixing Sex’; D. Griffiths ‘Hypospadias and the Performative, Psychological and
Perfect Penis’, in B. Ashton, A. Bonsall, J. Hay, eds., Talking Bodies Vol. II (London:
Palgrave, 2020), pp. 143–166.
31. S. Creighton, C.L. Minto and S.J. Steele, ‘Objective Cosmetic and Anatomical Outcomes at
Adolescence of Feminising Surgery for Ambiguous Genitalia Done in Childhood’, The
Lancet 358 (2001), pp. 124–125.
32. C. Benetti-Pinto et al., ‘Factors Associated with the Reduction of Bone Density in Patients
with Gonadal Dysgenesis’, Fertility and Sterility 77 (2002), pp. 571–575; K. Rubin, ‘Turner
Syndrome and Osteoporosis: Mechanisms and Prognosis’, Pediatrics 102 (1998), pp. 481–
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preserving fertility, early removal of testes in childhood makes this an impossibility.
There is also evidence that the cancer risks associated with intersex variations have
been inflated leading to overdiagnosis and unnecessary gonadectomies.33 As these
surgeries remain experimental, the likelihood of indirect negative consequences are
also high, including sepsis, infection and death.34 As with other experimental inter-
ventions on children, these risks are rarely acknowledged.35 Assigning to the wrong
sex/gender is also possible with one clinical review finding that children with certain
intersex traits changed from their assigned gender in between 39% and 64% of cases.36
There is evidence that clinicians do acknowledge some of these risks in their consulta-
tions, but they concomitantly fail to discuss the possibility that ‘these early genital
surgeries may also produce suffering, social alienation, and trauma later in life’.37
Accordingly, such surgeries raise serious ethical and legal concerns. These concerns
are heightened when they are performed for non-therapeutic reasons. As the UN
Special Rapporteur on Torture stated:
485; S. Mora et al., ‘Effect of Estrogen Replacement Therapy on Bone Mineral Content in
Girls with Turner Syndrome’, Obstetric Gynaecology 79 (1992), pp. 747–751.
33. L.H.J. Looijenga et al., ‘Tumor Risk in Disorders of Sex Development (DSD)’, Best Practice
& Research Clinical Endocrinology & Metabolism 21(3) (2007), pp. 480–495.
34. L.C. Wang and D.P. Poppas, ‘Surgical Outcomes and Complications of Reconstructive
Surgery in the Female Congenital Adrenal Hyperplasia Patient: What Every
Endocrinologist Should Know’, The Journal of Steroid Biochemistry and Molecular
Biology 165 (2017), pp. 137–144; I. Hughes et al., ‘Consequences of the ESPE/LWPES
Guidelines for Diagnosis and Treatment of Disorders of Sex Development’, Best Practice &
Research Clinical Endocrinology & Metabolism 21(3) (2007), pp. 351–365 at 363; P.
Hegarty and C. Chase, ‘Intersex Activism, Feminism and Psychology: Opening a
Dialogue on Theory, Research and Clinical Practice’, Feminism & Psychology 10(1)
(2000), pp. 117–132.
35. M. Fox, M. Thomson, and J. Warburton, ‘Embodied Integrity, Shaping Surgeries and the
Profoundly Disabled Child’, in C. Dietz, M. Travis and M. Thomson, eds., A Jurisprudence
of the Body (London: Palgrave, 2020), pp. 281–314.
36. P. Cohen-Kettenis, ‘Gender Change in 46, XY Persons with 5a-Reductase-2 Deficiency and
17b-Hydroxysteroid Dehydrogenase-3 Deficiency’, Archives of Sexual Behavior 34(4)
(2005), pp. 399–410. Note these are different intersex variations to the ones we have been
discussing but outline some of the problems in surgically assigning sex. In CAH, for
example, around 5.2% of 46, XX CAH individuals experience gender dysphoria.
Approximately 1/3 of these individuals (<2%) opt to live as males, generally after
adolescence. A.B. Dessens, F.M.E. Slijper and S.L.S. Drop, ‘Gender Dysphoria and
Gender Change in Chromosomal Females with Congenital Adrenal Hyperplasia’, Archives
of Sexual Behavior 34 (2005), pp. 389–397; L.E. de Jesus, E.C. Costa and S. Dekermacher,
‘Gender Dysphoria and XX Congenital Adrenal Hyperplasia: How Frequent Is It? Is Male-
Sex Rearing a Good Idea?’, Journal of Pediatric Surgery 54(11) (2019), pp. 2421–2427.
37. S. Timmermans, A. Yang, M. Gardner, et al., ‘Gender Destinies: Assigning Gender in
Disorders of Sex Development-Intersex Clinics’, Sociology of Health & Illness 41(8)
(2019), pp. 1520–1534 at 1527.
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. . . genital-normalizing surgeries [performed] under the guise of “reparative thera-
pies” . . . are rarely, if ever, medically necessary, lead to severe and life-long physical and
mental pain and suffering and can amount to torture and ill-treatment.38
Current international guidelines on optimal clinical
management
In 2006, over 50 international paediatric endocrinologists met to review the management
and long-term outcomes of ‘intersex disorders’.39 The result of this Conference was the
‘Consensus Statement on Management of Intersex Disorders’ which sets out clear gen-
eral concepts of care for children born with ‘Disorders of Sexual Development’, the
preferred terminology of the Consensus Statement.40 In particular, with regard to optimal
clinical management, it states:
1. gender assignment must be avoided before expert evaluation in newborns;
2. evaluation and long-term management must be performed at a centre with an
experienced multidisciplinary team (MDT);
3. all individuals should receive a gender assignment;
4. open communication with patients and families is essential, and participation in
decision-making is encouraged; and
5. patient and family concerns should be respected and addressed in strict
confidence.41
Most importantly, the Consensus Statement emphasises that the complex needs of
children with intersex variations require an MDT comprised of experienced ‘pediatric
subspecialists in endocrinology, surgery and/or urology, psychology/psychiatry, gyne-
cology, genetics, [and] neonatology’. The Consensus Statement also stated that, if avail-
able, MDTs should include social work, nursing and medical ethics, although it
acknowledged that the team would reflect ‘DSD type, local resources, context, and
location’.42 The significance of the disciplines is illustrated by the duties they are
responsible for, as detailed by Gomez-Lobo in Table 1.
The Consensus Statement also stresses the importance of ongoing communication
with the individual’s GP, and that ‘Psychosocial care provided by mental health staff
38. UN Human Rights Council, Report of the Special Rapporteur on Torture and Other Cruel,
Inhuman or Degrading Treatment or Punishment, Juan E. Mèndez, 5 January 2016, A/HRC/
31/57, at para 48.
39. Lee, Nordenström, Houk, et al., ‘Global Disorders of Sex Development Update Since 2006’,
p. 170.
40. The Consensus Statement recommended adoption of the term ‘Disorders of Sex
Development’. This recommendation was accepted almost universally by the medical
profession despite resistance from some patient advocates and service users. See Munro
et al., ‘Intersex, Variations of Sex Characteristics, and DSD’.
41. Lee, Nordenström, Houk, et al., ‘Global Disorders of Sex Development Update Since 2006’.
42. Op. cit.
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with expertise in DSD should be an integral part of management to promote positive
adaptation’.44 When updated in 2016, it was added that ‘education and psychological
support was needed . . . to [allow individuals to] make sense of the condition, relate to
their community and establish relationships’.45 Notably, psychosocial support is
Table 1. Members of the MDT and their roles.43
Specialist Role
Psychologist or Psychiatrist Perform evaluation and management of the mental health needs
of the child; assess the child’s ability to participate in decision-
making; assess and facilitate the parent or child relationship;
referral for mental health needs of parents
Geneticist or genetic
counsellor
Perform proper genetic diagnostic tests; provide genetic
counselling for the family and child as well as assess for the
need to evaluate other family members
Paediatric endocrinologist Perform evaluation and management of endocrine disorders;
provide hormonal management for all endocrine needs
including growth and puberty induction
Paediatric urologist Perform evaluation and management of urologic concerns;
perform surgeries after thorough discussion with the team
and family
Paediatric gynaecologist Perform evaluation and management of urologic concerns;
perform surgeries after thorough discussion with the team
and family
Paediatric surgeon In some institutions, general paediatric surgeons provide
surgical care
Neonatologist Provide care for children with DSD and other associated
conditions which require care such as salt-wasting
Nursing and social worker Coordinate care and provide educational help to patients and
families; communicate with the team and family; occasionally
provide mental health services; connect families with
resources and support services
Bioethicist Assist in medical decision-making, especially in cases when
opinions differ regarding what constitutes the child’s best
interest; assist in developing hospital policy regarding legal
issues
Others Medical interpreter: it is important to use a trained medical
interpreter when English is not the family’s first language
MDT: multidisciplinary team.
43. Table from V. Gomez-Lobo, ‘Multidisciplinary Care for Individuals with Disorders of Sex
Development’, Current Opinion in Obstetrics and Gynecology 26(5) (2014), pp. 366–371 at
368. They took and modified the table from the Accord Alliance Handbook. Available at:
http://www.accordalliance.org/wp-content/uploads/2013/07/clinical.pdf (accessed 4
September 2019).
44. Lee, Nordenström, Houk, et al., ‘Global Disorders of Sex Development Update Since 2006’.
45. Op. cit., p. 170.
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considered crucial for the child and their family to ensure ‘the best possible set of
decisions [are reached] in the circumstances’.46 Recently, one of the UK’s leading
providers of intersex healthcare, Great Ormond Street Hospital (GOSH), was criticised
over failures to provide psychological support to patients. We would expect NHS Eng-
land to have learnt from and engaged with this psychosocial need. The 2016 update also
emphasised the need for MDTs to engage with peer support.47
While the Consensus Statement recommends deferring non-therapeutic medical
interventions, it also points towards a body of literature suggesting that ‘surgery . . .
performed for cosmetic reasons in the first year of life relieves parental distress and
improves attachment between the child and the parents’.48 It also states that ‘systema-
tic evidence for this belief is lacking’.49 Nevertheless, non-therapeutic interventions
appear routinely recommended and practised, and a recent study found these beliefs
persist among many healthcare professionals.50 These practices have been the focus of
the international criticism we have noted and the activities of international activists and
support groups.
The Consensus Statement produced thorough guidelines in this area, but in the
absence of clear NHS policy, little is known as to whether individual NHS England
hospitals are adhering to the Consensus Statement’s General Code of Practice. A number
of organisations including the Society for Endocrinology UK (SEUK)51 and the British
Society for Paediatric Endocrinology and Diabetes (BSPED)52 have each developed
UK-specific guidance in this area, but it is unclear whether these are being followed
in place of international guidelines or at all. Moreover, while these guidelines affirm the
need for an MDT, there are some problematic differences in their composition (as we
address below) that could limit the extent to which the United Kingdom can be viewed as
delivering optimal care. To address this gap in knowledge and explore how children with
intersex variations are managed, we conducted an FoI exercise to map out medical
practice in this area. Such an evaluation is important and timely given that the UK
Government and the NHS are considering medical standards and that controversial
46. Op. cit.
47. Op. cit.
48. P. Lee et al., ‘Consensus Statement’ (e491) (2006). C. Wolfe-Christensen, A.B. Wisniewski,
A.J. Mullins, et al., ‘Changes in Levels of Parental Distress After Their Child with Atypical
Genitalia Undergoes Genitoplasty’, Journal of Pediatric Urology 13 (2017), pp. 32.e31–32.
e36.
49. Lee, Houk, Ahmed, et al., ‘In Collaboration with the Participants’.
50. L-M. Liao, P. Hegarty, S. Creighton, et al., ‘Clitoral Surgery on Minors: An Interview Study
with Clinical Experts of Differences of Sex Development’, BMJ Open 9(6) (2019), e025821.
51. S.F. Ahmed, J.C. Achermann, W. Arlt, et al., ‘UK Guidance on the Initial Evaluation of an
Infant or an Adolescent with a Suspected Disorder of Sex Development (Revised 2015)’,
Clinical Endocrinology 84(5) (2016), pp. 771–788.
52. British Society of Paediatric Endocrinology and Diabetes (BSPED), ‘Clinical Standards and
Principles of Management for Disorders of Sex Development’, (2017). Available at: https://
www.bsped.org.uk/media/1371/dsd-standards-november_2017.pdf (accessed 1 December
2020).
126 Medical Law International 21(2)
management strategies are a potential source of considerable stress for patients and
families.53 The findings presented here provide important evidence for reform consid-
erations in this area. They also have significance for other jurisdictions as the ethics and
legality of early management – specifically non-therapeutic surgery – is the focus for
increased national and supranational scrutiny.
Methods
FoI requests are an increasingly important methodological tool particularly in healthcare,
as ‘data obtained from multiple NHS trusts can provide a rich corpora of data swiftly’
that are not readily available within the public domain.54 This allows researchers to
engage in a wider consideration of the scope of the NHS and to access information that
prior to the Freedom of Information Act 2000 would have been difficult to access.55
While this process is cost-effective both in terms of time and resources, research has
shown that FoI requests also have a better response rate than other forms of data col-
lection such as questionnaires or letter-based requests.56 This section follows Fowler
et al.’s proposed methodological checklist to enable the research community to develop a
more standardised process of data collection through the use of FoI requests.57 Fowler
et al. recommend that methodological sections should include the following information:
1. Which body/bodies data were requested from
2. How many and what questions were asked
3. The rate and time frame or responses
4. Reasons given when data were not released
5. Amount of data received58
For our study, FoI requests were sent in July 2018 to 134 NHS bodies: all 131 acute
NHS Trusts, and 3 specialist children’s trusts as acute Trusts were unable to respond on
their behalf. One hundred and twenty-eight responded (95.2%), with 91.8% answering in
full. Reasons given for partial responses included that the cost exceeding the statutory
limit or that the data may make individuals identifiable. In some instances, there was no
justification. Thirty-one Trusts exceeded the 20 working day statutory time limit for
responses, with 6 failing to respond at all. Trusts were asked:
1. Who provides expert evaluation of gender assignment in children with DSD?
2. Does the Trust use an MDT that deals with the evaluation and long-term man-
agement and needs of patients with DSD?
3. What specialties are represented on the MDT?
53. Lee, Nordenström, Houk, et al., ‘Global Disorders of Sex Development Update Since 2006’.
54. A.J. Fowler, R.A. Agha, C.F. Camm, et al., ‘The UK Freedom of Information Act (2000) in
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4. When dealing with DSD, what guidelines, if any, do decision makers follow?
5. How many people have been referred to this team per year for the last 5 years?
The term ‘DSD’ was used instead of ‘intersex variation’ as this is the terminology
used by NHS Trusts. Our analysis accordingly refers to ‘DSD’. This does not mean,
however, that we approve of the term.59 While FoI requests were most suitable for this
exercise, this methodology has inevitable limitations. FoI requests cannot answer why
particular practices are adopted nor ascertain their wider impact: such questions require
further research. Moreover, ensuring consistency across the Trusts in terms of how they
gather information is problematic. The authors acknowledge these difficulties, particu-
larly given the lack of external corroboration of data.60 Nevertheless, the methodologies
employed by the Trusts displayed a logical internal consistency, producing detailed
information about the practices of the Trusts. Ultimately, this FoI was designed to initiate
and inform discussions regarding medical standards in this area and the exercise gener-
ated data appropriate for this.
Results
Of the 128 responses, we identified 15 Trusts that provide care, with 105 Trusts referring
patients to these ‘hub hospitals’.61 It is a concern that eight Trusts claimed they had no
engagement with the issues raised, or no guidelines on where to refer patients.62 Our
subsequent analysis focuses on the hub hospitals that provide care for children with
intersex variations. While this may seem like a small sample size, it captures all of the
MDTs working with children with intersex variations in England. All 15 are listed in
Table 2 with the number of hospitals referring patients to them and also the number of
patients that had been referred to the hub hospital’s MDT (Q5).
Of the 15 Trusts, only 9 gave full answers to Question 5 (number of patients referred).
Three refused due to the cost of compliance, two gave no reason for the unanswered
question and one acknowledged the data are not collected by the Trust. The data from
Table 2 also evidence insufficient record-keeping by the Trusts, with only four giving
answers not indicated to be an estimate. This limits the value of the data and compar-
ability of results. However, based on only the 9 hubs that responded (which, including
referring hospitals, account for 87 of the 120 Trusts who responded, 72.5%), there is an
average of between 220 and 227 MDT patient referrals a year. It is highly likely that the
number of patient referrals is greater given that six hub hospitals, predominantly located
59. See ‘Nomenclature Disclaimer’, p. 1.
60. M. Fox, M. Thomson and J. Warburton, ‘Non-Therapeutic Male Genital Cutting and Harm:
Law, Policy, and Evidence from UK Hospitals’, Bioethics 33(4) (2019), pp. 467–474.
61. This is our designation.
62. Chesterfield Royal Hospital NHS Foundation Trust, Countess of Chester Hospital NHS
Foundation Trust, East Cheshire NHS Trust, East Lancashire Hospitals NHS Trust,
Kettering General Hospital NHS Foundation Trust, South Tyneside NHS Foundation
Trust, St George’s Healthcare NHS Trust, West Suffolk NHS Foundation Trust.
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in the North, did not respond. Twenty-seven hospitals refer patients to these six hubs
meaning that altogether, we have no figures for 33 out of 120 NHS Trusts (27.5%).
In terms of MDTs, all except three hub hospitals stated that an MDT was responsible
for the expert evaluation of gender assignment in children with DSD (Question 1).
Newcastle, Doncaster and Bassetlaw, and Hull and East Yorkshire instead indicated that
a paediatric endocrinologist would be responsible for this evaluation. Newcastle elabo-
rated stating that expert evaluations are primarily provided by paediatric endocrine
consultants and newborns are ‘usually examined at a joint appointment with a consultant
paediatric endocrine and a consultant clinical geneticist and if possible a paediatric
surgeon who will see the family at the same appointment’.
In response to Questions 2 and 3 (the use and composition of MDT), all hub
hospitals – bar Hull and East Yorkshire – confirmed they relied on an MDT, although
the disciplines reflected on these specialist teams were subject to significant variance.
Table 3 provides details of the composition. Hull and East Yorkshire stated that ‘there
is not a specific team, but access to paediatric endocrinologist, paediatric urologist,
visiting regional geneticist, paediatric endocrine specialist nurse is available. The long-
term management is through the paediatric endocrine specialist clinic’. Hull’s speci-
alisms are included within Table 3. Nottingham declined to answer what specialisms
were involved in their MDT.
With the exception of Nottingham, Table 4 demonstrates all MDTs have access to an
endocrinologist and a surgeon/urologist; 86% have access to geneticists and psycholo-
gists; 64% have access to a gynaecologist; and 21% have access to a neonatologist.
Accordingly, we can see MDTs in the United Kingdom are not comprised of the staff
deemed essential by international guidelines designed to promote optimal care.
Table 2. Number of referrals to hub hospitals.
Trust No. of hospitals referring No. of patients
Addenbrookes 4 15–20 per year
Alder Hey 7 250 over 5 years
Birmingham 12 Approximately 120 over 5 years
Bristol 10 Approximately 2 per month
Doncaster 0 Data not collected by Trust
GOSH 31 135 over 5 years
Guys 2 49 over 3 years
Hull 0 Refused due to cost of compliance
Leeds 6 Refused due to cost of compliance
Manchester 10 Refused due to cost of compliance
Newcastle 6 Estimated 10–15 per year
Nottingham 2 Did not answer
Oxford 3 Average 50 per year
Sheffield 3 Probably 4–5 per year
Southampton 9 Did not answer
GOSH: Great Ormond Street Hospital.

























































































































































































































































































































































































































In terms of desired specialisms, as Table 5 indicates, inclusion is much more sporadic.
Only 57% of MDTs had access to a specialist nurse. Ethicists were only represented on
21% of MDTs and only one Trust had a social worker. ‘Other’ specialisms are mixed but
highlight the greater resources of GOSH – likely because of their dual public and private
status, geographic location and the large volume of hospitals that refer on to them.
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As set out in Table 6, the most frequently used guidelines were the BSPED Clinical
Standards and Principles of Management of Disorders of Sexual Development (2017)
and the SEUK Guidance on the Initial Evaluation of an Infant or an Adolescent with a
Suspected Disorder of Sex Development (Revised 2015): Four MDTs (Alder Hey,
Doncaster, Hull and Oxford) do not use the SEUK and three MDTs do not use the
BSPED (Addenbrookes, Guys and Newcastle). Only Birmingham, GOSH and Bristol
refer to the international DSD Consensus Statement. The examples of other literature
provided by Addenbrookes, Bristol and GOSH included the COST Action Working
Group’s DSD Consensus Statement,63 Evaluation and Treatment of Cryptorchidism,64
undefined literature purely referenced as ‘current’ and their own regional referral
guidelines. Once again, Nottingham refused to provide information as to what, if any,
guidelines they followed.
Discussion
The data that our exercise generated raise significant concerns regarding clinical record-
keeping, geographical variation in MDTs, use of clinical guidelines, the composition of
MDTs and professional hierarchies within the health sector. We address these in turn.


























63. M. Cools et al. on behalf of the COST Action BM1303 working group 1, ‘Caring for
Individuals with a Difference of Sex Development (DSD): A Consensus Statement’,
Nature Reviews Endocrinology 14 (2018), pp. 415–429.
64. Kolon et al. on behalf of the American Urological Association, ‘Evaluation and Treatment of
Cryptorchidism’, American Urological Association 2014. Available at: https://www.auanet.
org/guidelines/cryptorchidism-guideline (accessed 13 July 2020).
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Recording intersex variations
Our FoI requests demonstrate inconsistencies in the recording of intersex variations
resulting in a significant divergence of incidence rate. This is, to some extent, surprising
given the medicalisation of intersex. For example, in Doncaster, the data for the number
of DSD referrals were simply ‘not collected by the Trust’. Similarly, two Trusts did not
answer the question providing no explanation as to why and three Trusts failed to give
the answer due to cost. If the information had been properly and systematically recorded,
this would not be a difficult request to comply with. The failure to comply with our
requests points to a lack of systematic data collection, suggesting that clinicians are still
failing to carefully and systematically record and compile data on these issues. Of the
other Trusts, a further three were approximations, again highlighting a lack of precision
in data collection.
Improper data keeping is problematic as it challenges current assumptions about
incidence rates and therefore the scale of harm in this area. The ‘Global disorders of
sex development update since 2006’ statement, for example, notes that ‘Data are not
available to determine the exact frequency of specific DSD, while only a small
fraction of those with DSD require extensive multidisciplinary assessment to reach
a recommendation for gender assignment’.65 The potential harms of non-therapeutic
medical interventions are therefore minimised through appeals to their relative rarity
despite the lack of evidence to back up such a claim. Unfortunately, it is not
possible to use the FoI data to comment on the incidence rate of intersex variations,
particularly given that we do not know which variations are/are not being referred to
the MDT (e.g. hypospadias) or exactly when (newborn or adolescence). Neverthe-
less, our numbers suggest that the referral rate is higher than Sax’s claim of 1 in
4500–5000.66 Even with the refusal of some MDTs to provide data, our research
points to a figure closer to 1 in 3000. Given this figure does not account for 27.5%
of Trusts in England, we speculate that it may well be higher but acknowledge that
more research is desperately needed. This is compounded by historical evidence
demonstrating that families often keep intersex variations a secret from their
doctors.67
Second, the contested nature of the term ‘DSD’ within medical categorisation means
that some instances of non-therapeutic medical interventions on children may not be
recorded or are being recorded under a different clinical code. In relation to the NHS,
Creighton et al. found that despite the introduction of an international consensus state-
ment recommending deferral of intersex surgeries in 2006, there was nevertheless con-
sistent recourse to gonadectomy, bilateral excision of testes, oophorectomy, operations
on the clitoris, vaginoplasty, operations on labia, plastic operations on the penis and
hypospadias masculinising operations on children up to the age of 14 between 2000 and
65. Lee, Nordenström, Houk, et al., ‘Global Disorders of Sex Development Update Since 2006’,
p. 159.
66. Sax, ‘How Common Is Intersex?’, p. 177.
67. G. Mak, Doubting Sex: Inscriptions, Bodies and Selves in Nineteenth-Century
Hermaphrodite Case Histories (Manchester: Manchester University Press, 2013).
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2014.68 While not all of these may be instances of DSD, they highlight the high levels of
surgical interventions on the bodies of children within the context of the NHS, suggest-
ing that the 2006 Consensus Statement has failed to impact medical practice. Other
research has similarly suggested that surgical practice in relation to intersex variations
have not altered in recent years.69 Munro et al. use these findings to conclude that there is
an ‘implementation deficit regarding the 2006 Consensus Statement Guidelines, which is
a matter of pressing concern, given the evidence that early childhood surgical procedures
can be harmful and that poor prognosis is common’.70
A third linked issue arises from these two points. The lack of systematic data collec-
tion makes it impossible to evidence how often and when non-therapeutic medical
interventions are happening. Medical professionals continue to claim that practices and
techniques have improved, that surgical interventions are rare and that anecdotal
accounts of harm from intersex activists are therefore not based on current practice.71
All of this means that it is incredibly difficult to make informed national policy decisions
in either the medical or legal sphere. Attempts to improve intersex care to support
intersex people are therefore hampered by the lack of systematic data collection.
Guidelines
The results identified two main sources of guidelines: the BSPED and the SEUK guide-
lines. The BSPED guidelines are brief and refer only to the composition of MDT and key
bullet-point recommendations for the care of patients with DSD. In contrast, the SEUK
guidelines are more comprehensive and mirror, in many ways, the international guide-
lines in the field. This is unsurprising given that one of the authors of the SEUK’s
guidelines was also an author of the international consensus. Nonetheless, there are some
differences in the recommended MDT composition which are unexplained by the text.
Moreover, there are differences between the listed MDT composition within the text and
the table offered within the SEUK guidelines.72
One issue raised by MDT reliance on these guidelines is that while they may result in
consistent management practices, their primary focus on endocrinology means they are
not fully utilising the interdisciplinary potential of MDTs. Indeed, the SEUK guidelines
68. S.M. Creighton, L. Michala, I. Mushtaq, et al., ‘Childhood Surgery for Ambiguous Genitalia:
Glimpses of Practice Changes or More of the Same?’, Psychology & Sexuality 5(1) (2014),
pp. 34–43.
69. P.D. Mouriquand et al., ‘Surgery in Disorders of Sex Development (DSD) with a Gender
Issue: If (Why), When, and How?’, Journal of Paediatric Urology 12 (2016), pp. 139–149;
K.P. Wolffenbuttel and N.S. Crouch, ‘Timing of Feminising Surgery in Disorders of Sex
Development’, Endocrinology Developments 27 (2014), pp. 210–221.
70. Munro et al., ‘Intersex, Variations of Sex Characteristics, and DSD’, p. 15.
71. M. Cools, M. Simmonds, S. Elford, et al., ‘Response to the Council of Europe Human Rights
Commissioner’s Issue Paper on Human Rights and Intersex People’, European Urology 70
(2016), pp. 407–409.
72. Ahmed, Achermann, Arlt, et al., ‘UK Guidance on the Initial Evaluation’. Compare, for
example, the list given on page 772 with the table provided on page 773.
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specifically state that ‘the paediatric endocrinologist assumes the role of clinical lead and
oversees the timely involvement of other members of the team’.73 The reliance on these
specialisms may further compound the homogeneity of care pathways offered and limit
any impact of the non-medical specialisms on MDTs. As Table 7 demonstrates, the
BSPED does not contain any reference to additional specialisms while the SEUK guide-
lines separately recommend that MDTs should have wider links to an MDT team con-
sisting of specialists ‘from adult endocrinology, plastic surgery, gynaecology, clinical
genetics, clinical biochemistry, adult clinical psychology and social work and, if possi-
ble, to a clinical ethics forum’.74 It is notable that adult endocrinology and plastic surgery
are at the top of this list and a ‘possible’ ethics forum is last. Despite the lead author
having been part of the consensus statement drafting, there is no explanation given as to
why the UK guidelines should differ so markedly from the international consensus other
than ‘some areas [of the consensus statement] were not covered in sufficient detail’.75
The UK approach in these guidelines problematically places a greater emphasis on an
endocrinologist/urologist model and on surgery: unlike the Consensus Statement, the
Table 7. A comparison of guidelines-suggested essential MDT composition.
Staff
International


























Social worker Social worker





MDT: multidisciplinary team; BSPED: British Society for Paediatric Endocrinology and Diabetes; SEUK: Society
for Endocrinology UK.
73. Ahmed, Achermann, Arlt, et al., ‘UK Guidance on the Initial Evaluation’, p. 772.
74. Op. cit., p. 772.
75. Op. cit., p. 771.
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SEUK guidelines do not recommend deferring surgery but rather suggest that psycho-
logical support is available for parents so that they can be ‘informed of the controversies
around undertaking or withholding early genital surgery’.76
Furthermore, unlike the international guidelines, neither the BSPED nor SEUK
guidelines acknowledge the legal and ethical issues raised by non-therapeutic medical
interventions on the body of the intersex child. Although the SEUK guidelines make
passing reference to a possible ‘ethics forum’ in wider MDT links, it mentions nothing
else in this regard. As already noted, legal scrutiny of this area is intensifying at inter-
national level, with the UN making 40 recommendations on intersex issues in its con-
cluding observations since 2013. A number of these recommendations were made before
the drafting of the current guidelines. As such, there is a danger that NHS Trusts that rely
primarily on the UK guidelines may be falling behind international clinical and ethical
standards and, in particular, the Consensus Statement. While some leading UK endocri-
nologists have rejected the idea that non-therapeutic medical interventions may contra-
vene human rights obligations,77 we advocate a greater engagement with lawyers,
ethicists and patient-activists in order to ensure that international guidelines are appro-
priately followed.
We would therefore support a shift from the current endocrinologist/urologist-based
guidelines to a new interdisciplinary set of guidelines drawing more on psychological,
ethical and legal obligations. As Roen states, such a model allows ‘psychological health
care [to act as] the foundation upon which other kinds of health care may be built as
needed’.78 This will require a shift in funding from surgical management to a psycho-
social framework,79 something for the newly formed NHS specialised commissioning
group to consider. Moreover, it will require new guidelines to be developed in this area.
MDT composition and geographical variation
In general, our results show children with an intersex variation who enter the NHS will
be managed by an MDT. This is consistent with the Consensus Statement. However, the
meaning of ‘MDT’ is subject to a significant degree of geographical variation. While
endocrinologists and urologists are uniformly represented, only three MDTs contain all
specialisms considered essential by the Consensus Statement or even UK guidelines. In
particular, there is a distinct lack of neonatologists. In the United Kingdom, this could
perhaps be explained by the division of neonatology as a distinct branch of paediatric
medicine within the NHS. Neonatologists primarily deal with instances of acute care in
newborns and so are primarily housed within Neonatal Intensive Care Units. This siloing
of medical and professional expertise through the NHS may lead to their lack of repre-
sentation on MDT and may also explain why some of the UK-adapted guidelines are less
76. Op. cit., p. 773. Our emphasis.
77. Cools et al., ‘Caring for Individuals’.
78. Roen, ‘Intersex or Diverse Sex Development’.
79. L-M. Liao, E. Tacconelli, D. Wood, et al., ‘Adolescent Girls with Disorders of Sex
Development: A Needs Analysis of Transitional Care’, Journal of Pediatric Urology 6
(2010), pp. 609–613.
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prescriptive about having a neonatologist on the MDT.80 The lack of gynaecologists,
however, is less easy to explain and needs further research and assessment.
While it is positive that psychologists are represented in 12 out of 15 Trusts, the
inclusion of other specialisms or sub-specialisms desired by the Consensus State-
ment is extremely limited with nursing, ethics, social work and social care rarely if
ever included. This is perhaps unsurprising given the narrow MDT composition
within UK guidance. GOSH is an exception in this regard (although this may be
due to the media scrutiny it received regarding care in 2017).81 Bristol is also
notable in terms of promising practice. Only two hub hospitals specifically referred
to parents either as part of the MDT or consulting with the MDT, and no reference
was made by any of the Trusts to peer support groups. While silence does not
necessarily indicate that MDTs are not engaging with parents or peer support
groups, it is perhaps indicative of a hierarchy between medical specialisms and
those constructed as being outside of the MDT. Intersex children and their families
are signposted towards peer support instead of this being built into the MDT them-
selves. Such an approach follows the recommendation of the SEUK guidelines and
shows another disjuncture between national and international approaches. Further
research is needed to ascertain what level of input such groups are playing at the
various hubs, particularly given that they can play an important role in decisions
made over care pathways.82 In terms of variations in MDT composition, Gomez-
Lobo found that gaps in disciplinary representation may be due to the result of lack
of available expertise. Thus, it is imperative that financial, administrative and tech-
nical support is provided to ensure MDTs consist of the appropriate specialisms
required to best support children with intersex variations.83
Perhaps the most concerning aspect of the results is the lack of appropriate psycho-
logical support for children and their families in areas served by Doncaster and Hull hub
hospitals. There is also emerging evidence that even where psychological support is
available it is not centred around the needs and experiences of intersex service users. In
the United Kingdom, service users are being referred to Gender Identity Development
80. The BSPED do not include a neonatologist. BSPED (2017), p. 1. The Society for
Endocrinologists ‘UK guidance’ sets out neonatologist as a clinical member of the MDT,
but not part of the core MDT team. Moreover these guidelines refer to either a neonatologist
or a general paediatrician. See Ahmed, Achermann, Arlt, et al., ‘UK Guidance on the Initial
Evaluation’, p 773. See Table 2 above.
81. F. Kirkland, ‘Great Ormond Street Hospital Failing Intersex Children’, BBC News 12
October 2017. Available at: https://www.bbc.co.uk/news/uk-41593914 (accessed 8 July
2020).
82. Y.K. Bartlett and N.S. Coulson, ‘An Investigation into the Empowerment Effects of Using
Online Support Groups and How This Affects Health Professional/Patient Communication’,
Patient Education and Counselling 83 (2011), pp. 113–119; S.M. Creighton, C.L. Minto,
L-M. Liao, et al., ‘Meeting Between Experts: Evaluation of the First UK Forum for Lay and
Professional Experts in Intersex’, Patient Education and Counselling 54 (2004), pp. 153–
157; Karzakis, ‘Fixing Sex’.
83. Gomez-Lobo, ‘Multidisciplinary Care for Individuals’.
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Services. These services are in high demand and are largely based upon the experi-
ences of trans service users. As a result, intersex children and their parents have
reported anecdotally being discharged after one session, as they do not display signs
of gender dysphoria.84 This may confirm Horowicz’s concern that the use of diag-
nostic criteria in referrals to Gender Identity Development Services are proble-
matic.85 Moving away from imprecise and limited diagnostic criteria would allow
for ‘individually focussed psychological support and monitoring from clinicians
across a child’s development. This approach would provide an ongoing develop-
mental commitment, through a positive and proactive approach, to understanding the
individual psychological needs of each child’.86 Taking these points in conjunction
with the findings of our study may indicate a lack of continuing support available
for intersex children and their families. It may also point towards a need for serious
and specific training for psychologists around intersex issues as well as the need for
more funding to be made available for these services. While our study focused on
the experiences of children, it is worth noting that there is only one MDT available
to adults in the entirety of England.
Relatedly, the BSPED and SEUK guidelines recommend that MDTs should include
radiologists. This was the case for only two of the Trusts despite most of them following
the BSPED guidelines. Consequently, the data highlight significant geographical varia-
tion in the make-up of MDTs with subsequent effects on optimal clinical care for
intersex children and their families.
MDTs and disciplinary hierarchies
The common presence of a psychologist in MDTs intimates that psychosocial needs are
generally seen as an integral aspect of care. However, the inclusion of these specialisms
must be taken with some degree of caution: the results cannot reveal how or when the
psychologist is involved. Elsewhere, commentators have highlighted a failure to engage
in genuine multidisciplinary work so that alternative approaches and frameworks have
not been explored. This has been particularly frustrating for the integration of psychol-
ogy into MDTs. As Liao et al. note, although ‘multi-disciplinary care pathways
for . . . DSDs often allude to the importance of psychological interventions, [they] . . . are
usually set up without due considerations of them’.87 Liao and Roen conducted inter-
views with 32 MDT members and found psychologists risk being marginalised as their
expertise is seen as peripheral. This can see them working in parallel and separate to the
84. Private Communication with the Author. More research is needed in this area.
85. E. Horowicz, ‘Rethinking “Need” for Clinical Support in Transgender and Gender Non-
Conforming Children Without Clinical Classification: Learning from “the Paper I Almost
Wrote”’, Bioethics (2020), pp. 1–9. Available at: https://doi.org/10.1111/bioe.12824
(accessed 19 November 2020).
86. Op cit.
87. P.M. Chadwick, A. Smyth and L-M. Liao, ‘Improving Self-Esteem in Women Diagnosed
with Turner Syndrome: Results of a Pilot Intervention’, Journal of Pediatric and Adolescent
Gynecology 27 (2014), pp. 129–132 at 131.
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main MDT.88 As they write, ‘the centrality of a medical process . . . was taken for granted
rather than negotiated. The classification of intersex traits as pathological dictates clinical
priorities and hierarchical arrangements, leaving very little space for psychosocial staff to
formulate different ideas and solutions’.89 MDTs often suffer from an absence of leader-
ship that sees them default towards a medicalised approach that favours ‘action’ over
deferral of treatment.90 Of our 15 hub hospitals, only GOSH has an MDT manager and
thus any evidence of an MDT organisational structure and, if hub hospitals are following
the SEUK guidelines, it is likely these teams are led by paediatric endocrinologists.
Accordingly, we remain sceptical as to how and when psychosocial care is being incor-
porated into care pathways. Offering alternative care pathways has not been the case under
the current endocrinologist-dominated model where clear hierarchies between healthcare
professionals persist. This affects the timings of when different specialists are brought into
the MDT with research suggesting that psychologists tend to be brought in after surgery has
taken place and where there is a perceived psychological problem (such as depression).91
Newcastle’s response to Question 1 demonstrates the potential for these hierarchies to play
out in practice, particularly how surgeons may influence the care management of children
with an intersex variation. Newcastle stated that examinations of newborn infants ideally
involve a paediatric surgeon who will also be present at the first meeting with the family. The
presence of a surgeon at such an early stage means they are well placed to influence the
parents’ decision-making process. In Newcastle’s first meeting, there is a notable absence of
psychological expertise. While our results do not disclose whether this experience is shared
in other Trusts, most responses stated the MDT would provide the expert evaluation, of
which the urologist/endocrinologist is consistently a central feature and where an MDT lead
is generally lacking. We share Liao et al.’s concerns that although ‘it is obvious that parents
affected by DSD first and foremost require sustained psychological support . . . this does not
seem to be the central focus in paediatric management’.92 Indeed, it may be understood more
as an afterthought. The absence of psychologists from initial discussions with families is
pronounced given that ‘they are likely to be the only team members with advance training in
communication in emotive environments’.93
88. L-M. Liao and K. Roen, ‘The Role of Psychologists in Multi-Disciplinary Teams for
Intersex/Diverse Sex Development: Interviews with British and Swedish Clinical
Specialists’, Psychology & Sexuality (2019), pp. 1–15 at 6. DOI: 10.1080/19419899.2019.
1689158.
89. Op. cit., p. 11.
90. Op. cit., p. 5.
91. Op. cit. See also A. Kyriakou, A. Dessens, J. Bryce, et al., ‘Current Models of Care for Disorders
of Sex Development – Results from an International Survey of Specialist Centres’, Orphanet
Journal of Rare Diseases 11 (2016), pp. 155–165, which suggested only 53% of initial
evaluations had a child psychologist present. The inclusion of psychologists in the United
Kingdom is above the average reported in an international study (69%).
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The downplaying of psychosocial support within MDTs has important consequences
for the ways in which parental concerns are understood and addressed. Timmermans
et al.’s direct observations of interactions between healthcare providers and caregivers in
DSD clinics found that clinicians frame gender in a biomedical way thus skewing the
process of gender assignment.94 Informed by caregivers’ already preconceived expec-
tations regarding the child’s future gender, clinicians are able to ‘marshal information
strategically to make certain decisions seem more appropriate than others’.95 Clinicians
and parents thus co-produce gender using a ‘medical rationale that absolves clinician and
parents from making the “wrong” choice’.96 Other research has raised important con-
cerns over the potential for healthcare professionals to ‘lead’ parents into making certain
decisions though the way they frame information.97 This framing may, in practice, shut
down dialogue between parents and medical professionals by presenting information as a
single unified collective.98 As Davis writes, ‘While this model can disperse medical
decision-making power, it also can reassert the authority of medical professionals over
intersex traits by vesting it in a group, not simply an individual’.99 Moreover, the lack of
MDT representation from psychiatrists, social workers and broader fields such as ethics,
bioethics, law, sociology or anthropology may be due to their greater potential to ‘reject
essentialist beliefs about sex, gender and sexuality’.100
The central role of a surgeon/urologist is particularly concerning when non-
therapeutic interventions are a primary concern for service users,101 advocacy groups102
and the international bodies that are increasingly critical of practice in this area. These
are non-medically indicated interventions that can be characterised as socially motivated
gender-‘normalising’ or ‘confirming’ surgeries.103 While each of the guidelines the
Trusts refer to acknowledge the merits of deferring surgeries, a recent study shows that
healthcare practitioners’ views continue to be shaped by the belief that surgery prevents
parental distress104 despite studies contesting this.105 Accordingly, many aspects of these
surgeries are still practised routinely. This is especially problematic given that interna-
tional condemnation stems from increasing awareness of the harms occasioned by early
non-therapeutic interventions,106 and the heightened ethical concern generated by their
94. Timmermans, Yang, Gardner, et al., ‘Gender Destinies’.
95. Op. cit.
96. Op. cit.
97. Roen and Hegarty, ‘Shaping Parents, Shaping Penises’, p. 978.
98. G. Davis, Contesting Intersex: The Dubious Diagnosis (New York, NY: New York
University Press, 2015).
99. Op. cit., 85.
100. Op. cit., 86.
101. Munro et al., ‘Intersex, Variations of Sex Characteristics, and DSD’.
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103. Creighton, Michala, Mushtaq, et al., ‘Childhood Surgery for Ambiguous Genitalia’.
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105. L. Michala, L-M. Liao, D. Wood, et al., ‘Practice Changes in Childhood Surgery for
Ambiguous Genitalia?’, Journal of Pediatric Urology 10 (2014), pp. 934–939.
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social rather than clinical motivation.107 This growing attention to harm can be under-
stood as part of a gradual shift in the acknowledgement of children as subjects who have
interests and are rights holders. We now consider these non-therapeutic interventions in
the context of the right to bodily integrity and a child’s right to participate in decision-
making that affects them.
Children’s rights
A number of the concerns raised highlight the continuing limitations of clinical engage-
ment with children’s rights. This may be unsurprising, as at a state level the evolution
and adoption of children’s rights has been uneven and, at times, piecemeal. In law,
Stalford et al. have argued that courts ‘across all jurisdictions routinely pursue limited,
often distinctly disempowering approaches to children’s rights’.108 In the United King-
dom, it has been argued that courts are still ‘only flirting with the idea that children are
rights-holders’.109 As Stalford et al. note, many courts:
. . . fail to engage with children’s rights issues, confining their adjudication to a factual
review of the available evidence rather than a more nuanced understanding of how that
evidence might be interpreted in the light of established children’s rights norms and
research intelligence.110
In response, this section foregrounds the children’s rights issues that are directly
engaged by the practices under review. Specifically, we note that non-therapeutic interven-
tions on the bodies of children with intersex variations raise significant concerns regarding
the fundamental rights of bodily integrity and self-determination. These human rights are
due respect from individual clinicians as well as the Trust administration, professional
organisations and devolved health services that regulate clinical practice. The recognition
and protection of children’s rights can help counter the dominant medical logic whereby
biological sex is ‘presented as relatively plastic’ and surgical and hormonal interventions are
‘the solution to problems of embodied intersex differences for self and society’.111
Academic attention has increasingly turned to the importance of bodily integrity as a
fundamental ‘psychological need’112 and ‘the cornerstone of all other liberties’.113
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Judicial attention too is beginning to acknowledge its importance in underpinning legal
rights.114 In the case of children, the importance of bodily integrity has recently been
explored in the context of non-therapeutic interventions. In a series of articles, Fox
et al.115 have argued that in best interest determinations the child’s right to bodily
integrity should outweigh other concerns, such as the more amorphous notion of family
integrity. In this regard, the authors develop the concept of embodied integrity. This
seeks to recognise not only the traditional ‘protective’ functions of bodily integrity
doctrine – the injunction to refrain from unwanted interference with the body – but also
the embodied nature of human existence.
Attending to embodiment directs us to acknowledge the body as the means through
which we interact with and experience the world. Interventions on the body are therefore
often biographical, shaping our life experiences and choices.116 Embodiment helps us to
understand the essential role of the body in the developing lives and identities of children
and alerts us to the potential impact of non-therapeutic interventions. As Roen writes:
‘The scarring, the aesthetic difference, the changes to sensation are lived continuously.
They are necessarily imbricated in the process of an emerging self’.117 While the
approaches of clinicians to their patients clearly differ,118 where the body is treated as
an abstract ‘malleable object’, the role of the body in constituting the emerging subject
and selfhood is ignored.119
The experience of children born with intersex variations who are subject to non-
therapeutic gender-‘normalising’ interventions demonstrates the need to respect the
embodied integrity of children and young people. While early non-therapeutic surgical
interventions are frequently characterised as one-off, they generally result in a child-
hood and early adulthood marked by additional reparative procedures. Early interven-
tions can also see children assigned to the wrong gender with the significant physical
and psychological harms this can entail. Evidence suggests that these risks are being
downplayed by clinicians.120 These unnecessary surgical interventions, motivated by
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social concerns, are clearly biographical, determining subsequent experiences of child-
and adulthood:
. . . surgery does reach beyond the superficial and even beyond the material, enabling a
different reality for the emerging self. For those who undergo surgery, the embodied self is
necessarily remoulded: surgery is never simply a ‘cosmetic’ endeavour.121
This underscores the importance of securing individual embodied choices. Fox et al. have
argued that in the case of non-therapeutic interventions on the bodies of children, respect
for embodied integrity mandates that such decisions are left until the young person is able
to make the decision themselves.122 This is a best interests decision that Garland and
Travis point out can be characterised by its deferability.123 This argument is increasingly
made by academics124 and policy bodies125 in the context of non-therapeutic male genital
cutting (‘circumcision’). The courts have also adopted this position when parents disagree
about the procedure. This, of course, begs the question why this right is only respected
when there is parental dispute.126 A growing body of literature promotes affording all
children, including those with intersex variations, the level of protection currently afforded
to female children.127 With intersex variations, while the international consensus statement
pays some lip service to delaying non-therapeutic intervention until the individual can
participate in decision-making, they continue to recommend surgeries as early as possi-
ble.128 In the processes of advocating surgical and medical intervention, much is elided:
121. Roen, ‘Clinical Intervention’, p. 15.
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The kinds of problems that are . . . left out, or not fully evaluated, concern those issues
pertaining to the future desires of the intersex person, or the future political perspective
and social opportunities of the intersex person, and issues to do with the complex involve-
ment of the body in the process of becoming.129
The concerns expressed here, and the embodied integrity model, engage the child’s
right to participate in decisions that affect them. Article 12(2) of the UN Convention on
the Rights of the Child (1989) provides that children should be heard and their views
given due weight in proceedings. In this regard, we support work that seeks to strengthen
the Article 12 right, which for many remains an ‘aspiration rather than reality’.130 Here
we would draw attention to the work of Aoife Daly who argues that the right to be heard
should be replaced by the ‘children’s autonomy principle’.131 Daly argues that children
should get to choose how they are involved in decision-making processes and the
outcome unless it is likely that significant harm will arise by following their wishes.132
Importantly, Daly equates best interests with children exercising their autonomy and
self-determination. We therefore support calls for children and young people with inter-
sex variations to be afforded greater autonomy. This is reflected in the right to self-
determination that non-surgical pathways aim to promote.133
Conclusions
Medical protocols on the management of intersex variations are under increased national
and international scrutiny. This is motivated, in part, by the non-therapeutic justifications
for many interventions and the significant harm that may follow. Harm to children in the
context of cosmetically or socially justified procedures is of particular ethical con-
cern.134 The UN Special Rapporteur on Torture summarised the direct and indirect
impact of such surgery:
In many States, children born with atypical sex characteristics are often subject to irrever-
sible sex assignment, involuntary sterilization and genital normalizing surgery, which are
performed without their informed consent or that of their parents, leaving them with per-
manent, irreversible infertility, causing severe mental suffering and contributing to stigma-
tization. In some cases, taboo and stigma lead to the killing of intersex infants.135
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While the Special Rapporteur details the surgeries performed without consent, and the
physical and social harms – including infanticide – that result, it has been argued that we
must also acknowledge embodied harms. That is, the damage done when a child is not
left to freely navigate his or her own body, embodied choices and possible futures. As
Roen writes:
. . . there must always be room for the atypically sexed child to imagine and to become, of
their own accord, rather than to simply respond to what has already been imagined for them.
Early genital surgery dangerously assumes that what was imagined by the adults will be
sufficient for, or ought to constrain, the desires of the intersexed child as s/he grows into
adulthood.136
This FoI exercise was designed to produce an overview of national practice in the
context of these harms and the increasing scrutiny and calls internationally for moratoria
on early non-therapeutic interventions they have provoked.137 It is worth highlighting,
therefore, that the FoI exercise detailed an almost exclusive reliance on guidance that is
biomedical in its focus and ultimately interventionist. These guidelines fail to engage
with the mounting legal and ethical concerns around these issues. The harms that are
being evidenced are consistently downplayed within these guidelines. More care needs
to be taken to place these medical interventions in their legal and ethical contexts.
Consequently, we would recommend a shift to an interdisciplinary set of guidelines
drawing upon law, ethics and psychosocial perspectives.
The exercise identified limited examples of promising practice in terms of the
composition of MDT. This is seen with GOSH and to a lesser extent Bristol. These
were, nevertheless, overshadowed by a widespread failure to include all specialisms
that the Consensus Statement set out as essential and desired to meet the complex
needs of children with intersex variations. Most notably, non-medical disciplines are
problematically absent in a situation that is often experienced as a ‘social emer-
gency’138 rather than a pressing biomedical or health concern. Access to specialist
treatment and care in this area will be significantly determined by geographical loca-
tion. NHS England must provide adequate resources and funding to enable MDT to
have an appropriate range of specialisms.
Our FoI exercise also found significant problems with record-keeping in this area.
There is a severe lack of systematic and comprehensive data collection, and the data that
are collected also lack precision. Accordingly, it is difficult to create policy and guidance
in an informed manner. We are concerned that this lack of data has been used to justify
non-therapeutic medical interventions. Thus, claims that intersex variations and their
poor and damaging medical management are ‘rare’ rely upon the medical profession’s
own systematic lack of data collection and poor administrative practices.
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Our data collection was restricted to NHS England. Practices in the devolved health
services require similar investigation. It is also important to address the broader context
of health and social care for individuals with intersex variations. This was beyond the
remit of the current exercise. However, this must be part of the broader reconsideration
of health responses. Further work is required to investigate support practices in the early
months and also longer term.139
Ultimately, our investigation revealed that current practice in English hospitals is
lagging behind moves in other jurisdictions to acknowledge the harms of early interven-
tion and the need to respect and promote children’s rights. In this, NHS England hos-
pitals may be out of step with what can be characterised as a developing human rights
norm.
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